Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | PRKCB | P05771 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22904111 | 0.91 | ADORA3 (0.34) | ADORA3DDB1CRBNPDPK1CCNB2 | |
| SCHEMBL22904494 | 0.86 | PDPK1 (0.42) | ADORA3DDB1CRBNPDPK1CCNB2 | |
| SCHEMBL22904495 | 0.86 | PDPK1 (0.42) | ADORA3DDB1CRBNPDPK1CCNB2 | |
| SCHEMBL22904410 | 0.86 | DDB1 (0.42) | ADORA3DDB1CRBNCA12CA1 | |
| SCHEMBL22904412 | 0.86 | DDB1 (0.42) | ADORA3DDB1CRBNCA12CA1 | |
| SCHEMBL22904102 | 0.82 | DDB1 (0.43) | ADORA3DDB1CRBNPDPK1CCNB2 | |
| SCHEMBL22904497 | 0.81 | CA1 (0.41) | PDPK1CCNB2PRKCBCDK1LYN | |
| SCHEMBL22904156 | 0.78 | IDO1 (0.43) | PDPK1CCNB2PRKCBCDK1LYN | |
| SCHEMBL22904409 | 0.77 | DRD2 (0.41) | ADORA3DDB1CRBNCA12CA1 | |
| SCHEMBL22904100 | 0.74 | DDB1 (0.52) | DDB1CRBNDRD2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021011631-A1 | FUSED-GLUTARIMIDE CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| US-20160331734-A1 | SUBSTITUTED N-ARYL PYRIDINONES | AUSPEX PHARMACEUTICALS, INC. | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160331734-A1 | SUBSTITUTED N-ARYL PYRIDINONES | COL1A1, COL2A1, COLGALT1 | ADORA3 2727/4885DDB1 2058/4885CRBN 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.